1. Spatial transcriptomics.
- Author
-
Anderson AC, Yanai I, Yates LR, Wang L, Swarbrick A, Sorger P, Santagata S, Fridman WH, Gao Q, Jerby L, Izar B, Shang L, and Zhou X
- Subjects
- Humans, Tumor Microenvironment genetics, Neoplasms genetics, Transcriptome
- Abstract
Spatial transcriptomics, with other spatial technologies, has enabled scientists to dissect the organization and interaction of different cell types within the tumor microenvironment. We asked experts to discuss some aspects of this technology from revealing the tumor microenvironment and heterogeneity, to tracking tumor evolution, to guiding tumor therapy, to current technical challenges., Competing Interests: Declaration of interests A.C.A. is a member of the SAB for Tizona Therapeutics, Trishula Therapeutics, Compass Therapeutics, Zumutor Biologics, Excepgen, and ImmuneOncia, which have interests in cancer immunotherapy. A.C.A. is also a paid consultant for iTeos Therapeutics and Larkspur Biosciences. A.C.A.’s interests were reviewed and managed by the Brigham and Women’s Hospital and Partners Healthcare in accordance with their conflict of interest policies. A.S. is a conjoint Associate Professor at UNSW Sydney. A.S. receives research support from Nanostring Technologies, 10X Genomics and Curio Biosciences. P.S. is a co-founder and member of the BOD of Glencoe Software, a member of the BOD for Applied Biomath, and a member of the SAB for RareCyte, NanoString and Montai Health; P.S. holds equity in Glencoe, Applied Biomath and RareCyte. P.K.S. is a consultant for Merck and the Sorger lab has received research funding from Novartis and Merck in the past five years. B.I. has received honoraria from consulting with Merck, Janssen Pharmaceuticals, AstraZeneca and Volastra Therapeutics. Other authors declare no competing interests., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF